deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT01938729

Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma

Phase I Study of Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Cholangiocellular Carcinoma) (ICC) Cholangiolar Carcinoma Intrahepatic Cholangiocarcinoma Peripheral Cholangiocarcinoma
Interventions DEXAMETHASONE FLOXURIDINE GEMCITABINE Liver resection and placement of hepatic artery infusion pump
Updated 11 times since 2017 Last updated: Sep 10, 2020 Started: Sep 5, 2013 Primary completion: Sep 10, 2020 Completion: Sep 10, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Cholangiocellular Carcinoma) (ICC) and Cholangiolar Carcinoma and is currently completed. Memorial Sloan Kettering Cancer Center leads this study, which shows 11 recorded versions since 2013 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotActive Not Recruiting~Feb 2017 – ~Oct 2017 · 8 months · monthly snapshotActive Not Recruiting~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshotActive Not Recruiting~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshotActive Not Recruiting~Oct 2018 – ~Oct 2019 · 12 months · monthly snapshotActive Not Recruiting~Oct 2019 – ~May 2020 · 7 months · monthly snapshotActive Not Recruiting~May 2020 – ~Oct 2020 · 5 months · monthly snapshotActive Not Recruiting~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Oct 2020 — Jan 2021 [monthly]

    Completed PHASE1

    Status: Active Not Recruiting → Completed

  5. May 2020 — Oct 2020 [monthly]

    Active Not Recruiting PHASE1

▶ Show 6 earlier versions

  1. Oct 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE1

  2. Oct 2018 — Oct 2019 [monthly]

    Active Not Recruiting PHASE1

  3. Jun 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE1

  4. Oct 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  5. Feb 2017 — Oct 2017 [monthly]

    Active Not Recruiting PHASE1

  6. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Sep 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
  • Ohio State University
  • University of Texas Southwestern Medical Center
  • Washington University School of Medicine
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations